March 3 | TICKER INSIDE

The weekend is almost here… AWARENESS STOCKS Hey Folks, The weekend is almost here… But there’s still plenty of trading left before the closing bell. And we’ve got some ????penny stocks to show you. With February behind us and March well under way, promoters have started to change up their mix, ending some campaigns and starting others. OKYO Pharma Ltd. (NASDAQ: OKYO) - February trading range: $1.90-$3.45 - Typical average daily volume: ~8,000 - Float: 21.14 million Guess how many topical treatments are FDA approved for ocular pain? Zero. The big goose egg. You might be thinking, “that’s a pretty obscure fact.” But did you know that Allergen’s eye Restasis ® Eye Drops for Chronic Dry Eyes is anticipated to generate around $2.3 billion in 2023 sales? Healthcare is unlike any other industry. Companies can carve out profitable multi-billion dollar niches with just a single drug or treatment. OKYO Pharma Limited (NASDAQ: OKYO), based out of London, focuses on novel molecules to treat inflammatory dry eye diseases and chronic pain. Its key objective: commercialize the first eye-treatment drug that combines anti-inflammatory and pain-reducing activity, currently known as OK-101. OK-101 is advertised as: OKYO’s Membrane Anchored Peptide (MAP) technology enabled the development of OK-101’s enhanced potential drug ‘residence’ time and potency at the ocular surface as well combating washout through inclusion of the lipid ‘anchor’ in the drug molecule. In layman’s terms - it’s a novel class of chemerin receptor agonists that reduces inflammation and pain simultaneously. The company also sees potential benefits for patients with ocular neuropathic pain, uveitis, and allergic conjunctivitis. Now, you might still e skeptical of the profit potential for such a limited product. But here’s some market size facts to consider: - Over 35% of people aged 50+ are affected by Dry Eye, with women representing two-thirds of the affected population. - It is estimated that globally, there are approximately 700 million people suffering from the disease. - Current treatments offer limited effectiveness and come with undesirable side effects. - Dry Eye Diseases cost the U.S. economy $55.4 billion annually. In late December of last year, the company announced the following: OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101 for the Treatment of Dry Eye Disease Essentially, this gives OKYO permission to start Phase 2, the first-in-human, clinical study for its product, testing its effectiveness. It’s worth noting that although this is a big step, 70% of drugs make it from Phase 1 to Phase 2. However, OK-101 was able to skip Phase 1 entirely. Management projects topline data to become available sometime in Q4 of this year. Financially, the company reported £1.6 million ($1.8 million) in total assets in September 2022, down from £3.3 million in March 2022. Additionally, cash on hand dropped from £2.1 million to £0.6 million ($0.7 million) during that same period. With a quarterly cash burn of $1.6 million and no revenues, the inevitable offering was tendered on February 17, with an assumed price of $2.21 per ADS, and a goal of raising $12 million to fund the Phase 2 trials. The company offered the following: - 5,429,864 ADS representing 352,941,160 ordinary shares - Pre-Funded Warrants to purchase up to 5,429,864 ADS - Up to 352,941,160 ordinary shares represented by ADS issuable upon exercise of the pre-funded warrants Unsurprisingly, the stock moved quite a bit that day, with shares trading from $2.40 to as high as $7.00 before closing at $3.74 on the day on over 20 million shares in trading volume. However, the stock saw little follow-through, with price dropping back down below $3.00 within three trading days. While there was an uptick on March 1, with nearly 8 million shares changing hands, the day’s price range remained muted between $2.15 and $3.01. From the technical side, promoters highlighted net insider buying in 2022, with net purchases of 7.475 million shares. [dPhrYBGxlaza_fUH-jqtxS7ys0HsGE5lpNNxCHSKwLnLJ_W76aA5k68Dt4UP7X2Ivbd6ul-eSBafgD1YngRPA8HHO1ONylcbN5GOlnPru7HXOZUmJPlRqXyHb-FCEUY1P9nhrcGurdN8u7Ea8tV-6dw] Source: NASDAQ.Com Promoters for this campaign received some hefty payments, with one company reporting $70,000 in compensation an another $250,000 for a two day marketing campaign that ended on February 28. That’s significantly larger than the $14,500 - $20,000 sums we discussed in Wednesday’s newsletter covering Mainz Biomend (NASDAQ: MYNZ). Straight to the Facts OKYO went public May 17, 2022, opening at $4.50 per share, trading as high as $6.11, but closing at $3.62. By the 23rd, shares closed below $3.00 and did not break $3.50 per share until the tender offering on February 17 of this year. It’s worth noting that the tender offering came roughly a week before noticed a promotional campaign. Whether any more ad dollars are spent before the Phase 2 trial topline results are announced is unclear. At minimum, it’s worth keeping the stock on your watchlist and checking on it as Q4 approaches. Always at your service, Baron Von Stocks Red Oak Media Group, 7940 Ann Arbor St Dexter MI USA 48130 To update contact information or unsubscribe from this list, please [click here](